SEC Tracker
Get the app

Mannatech MTEX

Mannatech Q1 FY24: revenue $29.4M, down 14%; diluted EPS $0.63

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Mannatech reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$29.4M−14% from $34.1M in Q3 FY2310-Q income statement, on EDGAR
  2. Net income$1.2M+95% from $604K in Q3 FY2310-Q income statement, on EDGAR
  3. Diluted EPS$0.63+97% from $0.32 in Q3 FY2310-Q income statement, on EDGAR
  4. Cash and cash equivalents$7.9M−42% from $13.7M in Q3 FY2310-Q balance sheet, on EDGAR
  5. Cash from operations$1.9M+39% from $1.4M in Q3 FY2310-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Mannatech files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2833 and related industry codes: the same peer list as the financial tables.

  1. LeonaBio ATHA public float $10M, Jun 30, 2025
  2. Traws Pharma ONTX public float $10M, Jun 30, 2025
  3. BioCardia BCDA public float $10M, Jun 30, 2025
  4. Alaunos Therapeutics TCRT public float $10M, Jun 30, 2025
  5. Scienture Holdings SCNX public float $10M, Jun 30, 2025